Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC
Open Access
- 25 May 2023
- journal article
- research article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 4 (9) , 100532
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancerAnnals of Oncology, 2018
- PD-L1 IHC in NSCLC with a global and methodological perspectiveLung Cancer, 2017
- Comparison of Different Decalcification Methods Using Rat Mandibles as a ModelJournal of Histochemistry & Cytochemistry, 2017
- PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lungRadiology and Oncology, 2017
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJournal of Clinical Oncology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialThe Lancet Oncology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016